Sorrento Therapeutics (NASDAQ:SRNE) is a development stage biopharmaceutical company that offers investors a short-term approval/commercialization opportunity in addition to a long-term investment in the company's innovative drug discovery platform.
Sorrento's lead product candidate, Cynviloq, is poised to enter various Phase III clinical trials for a variety of cancer indications including non-small cell lung cancer (NSCLC), metastatic breast cancer ((NYSE:MBC)) and prostate cancer (PC) en route to potential FDA approval via the 505(b)(2) bioequivalence pathway. Cynviloq is a new formulation of the powerful anti-cancer agent Taxol (paclitaxel) and is being developed as a bioequivalent to Celgene's (NASDAQ:CELG) Abraxane.
Abraxane, which is human serum albumin-bound paclitaxel, generated sales of $427 million...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|